Skip to main content

Novavax is part of the FDA’s COVID-19 booster debate, but its vaccine still hasn’t been authorized

The experimental shot played a front-and-center role during this week’s debate about how best to update the COVID-19 vaccines to better protect against omicron.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.